Literature DB >> 11019931

Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors.

S Peretti1, R Judge, I Hindmarch.   

Abstract

OBJECTIVE: An important consideration in the choice of an antidepressant is its safety and tolerability.
METHOD: We present a review of literature, clinical trials and meta-analyses regarding the safety and tolerability of the tricyclic antidepressants (TCAs) and the selective serotonin reuptake inhibitors (SSRIs) in depressed patients.
RESULTS: The SSRIs have a very favourable side-effect profile compared to the TCAs and are associated with fewer treatment discontinuations. Unlike the TCAs, they do not cause anticholinergic, hypotensive or sedating reactions, and are not associated with impaired cognitive function. Their most common side-effects (nausea, vomiting, nervousness, insomnia, headache and sexual dysfunction) are usually mild and typically disappear as treatment continues. The SSRIs also exhibit lower toxicity and lower lethality when taken in an overdose situation. Although the safety profiles of the principal SSRIs appear to be comparable, there is some data showing important differences in the severity and frequency of specific adverse events.
CONCLUSION: The SSRIs have a more favourable safety profile than the TCAs in both acute and long-term treatment of major depression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11019931     DOI: 10.1111/j.1600-0447.2000.tb10944.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand Suppl        ISSN: 0065-1591


  37 in total

Review 1.  Pathological laughing and crying : epidemiology, pathophysiology and treatment.

Authors:  Hal S Wortzel; Timothy J Oster; C Alan Anderson; David B Arciniegas
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 2.  The increasing frequency of mania and bipolar disorder: causes and potential negative impacts.

Authors:  Sean H Yutzy; Chad R Woofter; Christopher C Abbott; Imad M Melhem; Brooke S Parish
Journal:  J Nerv Ment Dis       Date:  2012-05       Impact factor: 2.254

Review 3.  Specifying the neuropsychology of affective disorders: clinical, demographic and neurobiological factors.

Authors:  Thomas Beblo; Grant Sinnamon; Bernhard T Baune
Journal:  Neuropsychol Rev       Date:  2011-06-10       Impact factor: 7.444

4.  Polypharmacy Among Adults Aged 65 Years and Older in the United States: 1988-2010.

Authors:  Christina J Charlesworth; Ellen Smit; David S H Lee; Fatimah Alramadhan; Michelle C Odden
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2015-03-01       Impact factor: 6.053

Review 5.  A meta-analysis of the effects of antidepressants on cognitive functioning in depressed and non-depressed samples.

Authors:  Catherine E Prado; Stephanie Watt; Simon F Crowe
Journal:  Neuropsychol Rev       Date:  2018-02-14       Impact factor: 7.444

6.  Newer antidepressants: evaluation of fatal toxicity index and interaction with alcohol based on Finnish postmortem data.

Authors:  Anna Koski; Erkki Vuori; Ilkka Ojanperä
Journal:  Int J Legal Med       Date:  2005-03-01       Impact factor: 2.686

7.  Perinatal Generalized Anxiety Disorder: Assessment and Treatment.

Authors:  Shaila Misri; Jasmin Abizadeh; Shawn Sanders; Elena Swift
Journal:  J Womens Health (Larchmt)       Date:  2015-06-30       Impact factor: 2.681

Review 8.  Do antidepressants reduce the burden imposed by depression on employers?

Authors:  Mark J Greener; Julian F Guest
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 9.  Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale.

Authors:  Jacob P R Jacobsen; Andrew D Krystal; K Ranga R Krishnan; Marc G Caron
Journal:  Trends Pharmacol Sci       Date:  2016-09-28       Impact factor: 14.819

10.  Evolving refractory major depressive disorder diagnostic and treatment paradigms: toward closed-loop therapeutics.

Authors:  Matthew P Ward; Pedro P Irazoqui
Journal:  Front Neuroeng       Date:  2010-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.